0.04% PHMB
Drug0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Other names: Polyhexamethylene Biguanide
NCT Number: NCT02506257
Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
The primary objective of the study is to establish the ocular safety and tolerability, and systemic safety of 3 different concentrations of preservative-free PHMB in healthy subjects. Safety and tolerability will be compared to those of a placebo.The PHMB bioavailability in plasma will also be assessed
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Other names: Polyhexamethylene Biguanide
0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Other names: Polyhexamethylene Biguanide
0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Other names: Polyhexamethylene Biguanide
PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
Time frame: up to 21 days from date of randomization
Time frame: Day14
Time frame: Baseline and Day 14
Change from baseline systolic blood pressure
Time frame: Baseline and Day 14
Change from baseline Visual acuity. Best corrected visual acuity was reported in decimal fraction. A decrease of visual acuity during treatment was considered a negative safety outcome.
Time frame: Baseline and Day 14
Change from baseline OSDI at D 14. Score range was betwwen 0-100. An increase of OSDI values with treatment represent a negative outcome.
Time frame: Baseline and Day 14
Change from baseline conjunctival staining at Day 14. Staining with lissamine green was used. The density of staining was graded with the Oxford Score. Score range was between 0-15. An increase in the score after treatment represent a negative outcome
SIFI SpA
Industry
Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07195864
Acanthamoeba Keratitis, Amebiasis
Madrid, Spain
View Trial DetailsNCT03484507
Acanthamoeba Keratitis, Amebiasis
Coimbatore, Tamil Nadu, India
View Trial DetailsNCT05110001
Acanthamoeba Keratitis, Amebiasis
São Paulo, Brazil
View Trial DetailsNCT06641882
Acanthamoeba Keratitis, Amebiasis
Brescia, Italy
View Trial Details